OTX-TP

Ocular Therapeutix, Inc. · Phase 2 active Small molecule

At a glance

Generic name	OTX-TP
Sponsor	Ocular Therapeutix, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert (PHASE3)
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT (PHASE3)
Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension (PHASE2)
Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OTX-TP CI brief — competitive landscape report
OTX-TP updates RSS · CI watch RSS
Ocular Therapeutix, Inc. portfolio CI